Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
64.92 USD | 0.00% | -0.50% | -19.76% |
May. 07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
May. 02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.76% | 80.95B | |
+33.07% | 698B | |
+26.51% | 568B | |
-4.28% | 358B | |
+18.90% | 328B | |
+3.74% | 283B | |
+16.36% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+7.27% | 165B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Transcript : Gilead Sciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 10